Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD
Published in The Lancet (British edition) (30.04.2016)
Published in The Lancet (British edition) (30.04.2016)
Get full text
Journal Article
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, Lesley, Prof, Bogaerts, Jan, PhD, Perrone, Andrea, MD, Ford, Robert, MD, Schwartz, Lawrence H, Prof, Mandrekar, Sumithra, Prof, Lin, Nancy U, MD, Litière, Saskia, PhD, Dancey, Janet, Prof, Chen, Alice, MD, Hodi, F Stephen, Prof, Therasse, Patrick, MD, Hoekstra, Otto S, Prof, Shankar, Lalitha K, MD, Wolchok, Jedd D, MD, Ballinger, Marcus, PhD, Caramella, Caroline, MD, de Vries, Elisabeth G E, Prof
Published in The lancet oncology (01.03.2017)
Published in The lancet oncology (01.03.2017)
Get full text
Journal Article
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer, Achim, MD, Barlesi, Fabrice, PhD, Waterkamp, Daniel, MD, Park, Keunchil, MD, Ciardiello, Fortunato, MD, von Pawel, Joachim, MD, Gadgeel, Shirish M, MD, Hida, Toyoaki, PhD, Kowalski, Dariusz M, PhD, Dols, Manuel Cobo, MD, Cortinovis, Diego L, PhD, Leach, Joseph, MD, Polikoff, Jonathan, MD, Barrios, Carlos, MD, Kabbinavar, Fairooz, MD, Frontera, Osvaldo Arén, MD, De Marinis, Filippo, MD, Turna, Hande, MD, Lee, Jong-Seok, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, He, Pei, PhD, Chen, Daniel S, MD, Sandler, Alan, MD, Gandara, David R, Dr
Published in The Lancet (British edition) (21.01.2017)
Published in The Lancet (British edition) (21.01.2017)
Get full text
Journal Article
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Patil, Namrata S., Nabet, Barzin Y., Müller, Sören, Koeppen, Hartmut, Zou, Wei, Giltnane, Jennifer, Au-Yeung, Amelia, Srivats, Shyam, Cheng, Jason H., Takahashi, Chikara, de Almeida, Patricia E., Chitre, Avantika S., Grogan, Jane L., Rangell, Linda, Jayakar, Sangeeta, Peterson, Maureen, Hsia, Allison W., O’Gorman, William E., Ballinger, Marcus, Banchereau, Romain, Shames, David S.
Published in Cancer cell (14.03.2022)
Published in Cancer cell (14.03.2022)
Get full text
Journal Article
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D
Published in Journal of clinical oncology (20.03.2018)
Published in Journal of clinical oncology (20.03.2018)
Get full text
Journal Article
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
Gandara, David R., von Pawel, Joachim, Mazieres, Julien, Sullivan, Richard, Helland, Åslaug, Han, Ji-Youn, Ponce Aix, Santiago, Rittmeyer, Achim, Barlesi, Fabrice, Kubo, Toshio, Park, Keunchil, Goldschmidt, Jerome, Gandhi, Mayank, Yun, Cindy, Yu, Wei, Matheny, Christina, He, Pei, Sandler, Alan, Ballinger, Marcus, Fehrenbacher, Louis
Published in Journal of thoracic oncology (01.12.2018)
Published in Journal of thoracic oncology (01.12.2018)
Get full text
Journal Article
MOSBY enables multi-omic inference and spatial biomarker discovery from whole slide images
Şenbabaoğlu, Yasin, Prabhakar, Vignesh, Khormali, Aminollah, Eastham, Jeff, Liu, Evan, Warner, Elisa, Nabet, Barzin, Srivastava, Minu, Ballinger, Marcus, Liu, Kai
Published in Scientific reports (06.08.2024)
Published in Scientific reports (06.08.2024)
Get full text
Journal Article
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Wu, Benjamin, Sternheim, Nitzan, Agarwal, Priya, Suchomel, Julia, Vadhavkar, Shweta, Bruno, Rene, Ballinger, Marcus, Bernaards, Coen A., Chan, Phyllis, Ruppel, Jane, Jin, Jin, Girish, Sandhya, Joshi, Amita, Quarmby, Valerie
Published in Clinical and translational science (01.01.2022)
Published in Clinical and translational science (01.01.2022)
Get full text
Journal Article
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
Patil, Namrata S, Zou, Wei, Mocci, Simonetta, Sandler, Alan, Ballinger, Marcus, Flynn, Susan, Kowanetz, Marcin, Hegde, Priti S
Published in PloS one (03.02.2021)
Published in PloS one (03.02.2021)
Get full text
Journal Article
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
Fehlings, Michael, Jhunjhunwala, Suchit, Kowanetz, Marcin, O’Gorman, William E., Hegde, Priti S., Sumatoh, Hermi, Lee, Boon Heng, Nardin, Alessandra, Becht, Etienne, Flynn, Susan, Ballinger, Marcus, Newell, Evan W., Yadav, Mahesh
Published in Journal for immunotherapy of cancer (12.09.2019)
Published in Journal for immunotherapy of cancer (12.09.2019)
Get full text
Journal Article
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
Peters, Solange, Galle, Peter R., Bernaards, Coen A., Ballinger, Marcus, Bruno, René, Quarmby, Valerie, Ruppel, Jane, Vilimovskij, Alexandr, Wu, Benjamin, Sternheim, Nitzan, Reck, Martin
Published in Clinical and translational science (01.01.2022)
Published in Clinical and translational science (01.01.2022)
Get full text
Journal Article
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial
Gadgeel, Shirish, Hirsch, Fred R., Kerr, Keith, Barlesi, Fabrice, Park, Keunchil, Rittmeyer, Achim, Zou, Wei, Bhatia, Namrata, Koeppen, Hartmut, Paul, Sarah M., Shames, David, Yi, Jing, Matheny, Christina, Ballinger, Marcus, McCleland, Mark, Gandara, David R.
Published in Clinical lung cancer (01.01.2022)
Published in Clinical lung cancer (01.01.2022)
Get full text
Journal Article
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
Chan, Phyllis, Marchand, Mathilde, Yoshida, Kenta, Vadhavkar, Shweta, Wang, Nina, Lin, Alyse, Wu, Benjamin, Ballinger, Marcus, Sternheim, Nitzan, Jin, Jin Y., Bruno, René
Published in CPT: pharmacometrics and systems pharmacology (01.10.2021)
Published in CPT: pharmacometrics and systems pharmacology (01.10.2021)
Get full text
Journal Article
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model
VanderPorten, Erica C, Taverna, Pietro, Hogan, Jennifer N, Ballinger, Marcus D, Flanagan, W Michael, Fucini, Raymond V
Published in Molecular cancer therapeutics (01.04.2009)
Published in Molecular cancer therapeutics (01.04.2009)
Get full text
Journal Article
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
Gandara, David, Reck, Martin, Moro-Sibilot, Denis, Mazieres, Julien, Gadgeel, Shirish, Morris, Stefanie, Cardona, Andres, Mendus, Diana, Ballinger, Marcus, Rittmeyer, Achim, Peters, Solange
Published in Journal for immunotherapy of cancer (01.03.2021)
Published in Journal for immunotherapy of cancer (01.03.2021)
Get full text
Journal Article
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
Zhou, Caicun, Srivastava, Minu K, Xu, Hao, Felip, Enriqueta, Wakelee, Heather, Altorki, Nasser, Reck, Martin, Liersch, Rüdiger, Kryzhanivska, Anna, Oizumi, Satoshi, Tanaka, Hiroshi, Hamm, John, McCune, Steven L, Bennett, Elizabeth, Gitlitz, Barbara, McNally, Virginia, Ballinger, Marcus, McCleland, Mark, Zou, Wei, Das Thakur, Meghna, Novello, Silvia
Published in Journal for immunotherapy of cancer (01.10.2023)
Published in Journal for immunotherapy of cancer (01.10.2023)
Get full text
Journal Article
601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC
Lu, Tianshi, Socinski, Mark A, Reck, Martin, West, Howard, Cappuzzo, Federico, Barlesi, Fabrice, Jotte, Robert M, Müller, Sören, Hamidi, Habib, Amitai, Assaf, Koeppen, Hartmut, Shames, David S, Ballinger, Marcus, Qamra, Aditi, Srivastava, Minu K, Nabet, Barzin
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
Srivastava, Minu K, Gayevskiy, Velimir, Ma, Vy, Estay, Ivette, Rodas, Miguel Lopez de, Rajendran, Barani Kumar, Hoang, Tien, Ballinger, Marcus, Amin, Reena, Herbst, Roy S, Marinis, Filippo de, Giaccone, Giuseppe, Jassem, Jacek, Spigel, David R, Schalper, Kurt, Koeppen, Hartmut, Shames, David S, Johnston, Robert, Giltnane, Jennifer M, Nabet, Barzin Y
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
Fragment-Based Discovery of Nonpeptidic BACE-1 Inhibitors Using Tethering
Yang, Wenjin, Fucini, Raymond V, Fahr, Bruce T, Randal, Mike, Lind, Kenneth E, Lam, Melissa B, Lu, Wanli, Lu, Yafan, Cary, Douglas R, Romanowski, Michael J, Colussi, Dennis, Pietrak, Beth, Allison, Timothy J, Munshi, Sanjeev K, Penny, David M, Pham, Phuongly, Sun, Jian, Thomas, Anila E, Wilkinson, Jennifer M, Jacobs, Jeffrey W, McDowell, Robert S, Ballinger, Marcus D
Published in Biochemistry (Easton) (02.06.2009)
Published in Biochemistry (Easton) (02.06.2009)
Get full text
Journal Article
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR)
Spira, Alexander I., Park, Keunchil, Mazières, Julien, Vansteenkiste, Johan F., Rittmeyer, Achim, Ballinger, Marcus, Waterkamp, Daniel, Kowanetz, Marcin, Mokatrin, Ahmad, Fehrenbacher, Louis
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article